Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $43.83.
A number of analysts have recently issued reports on the stock. Mizuho assumed coverage on shares of Cartesian Therapeutics in a research note on Friday, May 24th. They set a “buy” rating and a $40.00 price objective on the stock. SVB Leerink assumed coverage on shares of Cartesian Therapeutics in a research report on Tuesday, April 23rd. They set an “outperform” rating and a $39.00 price target for the company. HC Wainwright decreased their price target on shares of Cartesian Therapeutics from $54.00 to $49.00 and set a “buy” rating for the company in a research report on Wednesday, July 3rd. Leerink Partnrs reissued an “outperform” rating on shares of Cartesian Therapeutics in a research report on Tuesday, April 23rd. Finally, Canaccord Genuity Group raised their price target on shares of Cartesian Therapeutics from $38.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, July 3rd.
Check Out Our Latest Stock Analysis on Cartesian Therapeutics
Cartesian Therapeutics Trading Down 5.9 %
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($1.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($1.16). The firm had revenue of $5.84 million for the quarter. On average, sell-side analysts anticipate that Cartesian Therapeutics will post 2.67 EPS for the current year.
Hedge Funds Weigh In On Cartesian Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the business. Artal Group S.A. acquired a new position in Cartesian Therapeutics in the first quarter worth $5,939,000. American International Group Inc. acquired a new position in Cartesian Therapeutics in the first quarter worth $37,000. Vanguard Group Inc. acquired a new position in Cartesian Therapeutics in the first quarter worth $4,105,000. SG Americas Securities LLC acquired a new position in Cartesian Therapeutics in the first quarter worth $31,000. Finally, Delphi Financial Group Inc. acquired a new position in Cartesian Therapeutics in the first quarter worth $430,000. Institutional investors and hedge funds own 86.95% of the company’s stock.
Cartesian Therapeutics Company Profile
Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
Featured Articles
- Five stocks we like better than Cartesian Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- Why is the Ex-Dividend Date Significant to Investors?
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Consumer Discretionary Stocks Explained
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.